Tchem KLK14 Kallikrein-14

Protein Summary

Description

Serine-type endopeptidase with a dual trypsin-like and chymotrypsin-like substrate specificity. May activate/inactivate the proteinase-activated receptors F2R, F2RL1 and F2RL3 and other kallikreins including KLK1, KLK3, KLK5 and KLK11. May function in seminal clot liquefaction through direct cleavage of the semenogelin SEMG1 and SEMG2 and activation of KLK3. May function through desmoglein DSG1 cleavage in epidermal desquamation a process by which the most superficial corneocytes are shed from the skin surface. May be involved in several aspects of tumor progression including growth, invasion and angiogenesis. This gene encodes a member of the kallikrein subfamily of serine proteases that have diverse physiological functions such as regulation of blood pressure and desquamation. The altered expression of this gene is implicated in the progression of different cancers including breast and prostate tumors. The encoded protein is a precursor that is proteolytically processed to generate the functional enzyme. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2015]

Uniprot Accession IDs

• Q9P0G3
• A7UNK5
• Q1RMZ2
• Q6B089
• hK14

Gene Name

• KLK14

Ensembl ID

• ENST00000391802
• ENSP00000375678
• ENSG00000129437

Symbol

• KLKL6
• KLK-L6

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
protein domain	0.58
biological term	0.51
cell line	0.49
trait	0.46
cell type or tissue	0.44

Protein Classes

PANTHER Classes

Protein / ... / Serine Protease / Kallikrein-14

DTO Classes

Protein / Enzyme / Protease / Serine Protease / Kallikrein-14

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 54.77   (req: < 5)

Gene RIFs: 29   (req: <= 3)

Antibodies: 193   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 54.77   (req: >= 5)

Gene RIFs: 29   (req: > 3)

Antibodies: 193   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 8

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 17

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0